Statement of Changes in Beneficial Ownership (4)
17 November 2021 - 10:37AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Leen Ann M. |
2. Issuer Name and Ticker or Trading Symbol
Allovir, Inc.
[
ALVR
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer |
|
(Last)
(First)
(Middle)
C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/12/2021 |
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 11/12/2021 | | S(1) | | 14266 | D | $22.2647 (2) | 2294876 | I | See Footnote (3) |
| Common Stock | 11/12/2021 | | S(1) | | 500 | D | $23.1766 (4) | 2294376 | I | See Footnote (3) |
| Common Stock | 11/15/2021 | | S(1) | | 6122 | D | $21.9155 (5) | 2288254 | I | See Footnote (3) |
| Common Stock | 11/16/2021 | | S(1) | | 100 | D | $21.76 | 2288154 | I | See Footnote (3) |
| Common Stock | | | | | | | | 28000 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020. |
| (2) | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.81 to $22.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| (3) | Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| (4) | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.99 to $23.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| (5) | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.75 to $22.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Leen Ann M.
C/O ALLOVIR, INC.
139 MAIN STREET, SUITE 500
CAMBRIDGE, MA 02142 |
|
| Chief Scientific Officer |
|
Signatures
|
| /s/ Brett Hagen, as Attorney-in-Fact | | 11/16/2021 |
| **Signature of Reporting Person | Date |
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Mar 2024 to Apr 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Apr 2023 to Apr 2024
